Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Levodopa Toxicity

Levodopa Toxicity 25. Lesser RP, Fahn S, Snider SR, Cote LJ, Isgreen 27. Chase TN, Mouradian MM, Engber T. Motor re- early levodopa therapy in PD. Neurology. 1981; WP, Barrett RE. Analysis of the clinical problems sponse complications and the function of striatal 31:125-131. in parkinsonism and the complications of long- efferent systems. Neurology. 1993;43(suppl 6): 30. Bonet A-M, Loria Y, Santi-Hilaire M-H, Lher- term levodopa therapy. Neurology. 1979;29:1253- S23-S27. mitte F, Agid Y. Does long-term aggravation of 1260. 28. Peppe A, Dambrosia JM, Chase T. Risk factors for Parkinson’s disease result from nondopaminer- 26. De Jong GT, Meerwaldt JD, Schmitz PIM. Fac- motor response complications in L-dopa– gic lesions? Neurology. 1987;37:1539-1542. tors that influence the occurrence of response treated parkinsonian patients. Adv Neurol. 1993; 31. Shulman LM. Levodopa toxicity in Parkinson dis- variations in Parkinson’s disease. Neurology. 1990; 60:698-702. ease: reality or myth? reality—practice patterns 40:1344-1346. 29. Markham CH, Diamond SG. Evidence to support should change. Arch Neurol. 2000;57:406-407. EW DRUGS in medicine dyskinesia. She argues that fluctua- cause patients will not only contrib- have had the dramatic tions and dyskinesia were not de- ute to the answer but also receive impact of the introduc- scribed prior to the introduction http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Neurology American Medical Association

Levodopa Toxicity

JAMA Neurology , Volume 57 (3) – Mar 1, 2000

Levodopa Toxicity

Abstract

25. Lesser RP, Fahn S, Snider SR, Cote LJ, Isgreen 27. Chase TN, Mouradian MM, Engber T. Motor re- early levodopa therapy in PD. Neurology. 1981; WP, Barrett RE. Analysis of the clinical problems sponse complications and the function of striatal 31:125-131. in parkinsonism and the complications of long- efferent systems. Neurology. 1993;43(suppl 6): 30. Bonet A-M, Loria Y, Santi-Hilaire M-H, Lher- term levodopa therapy. Neurology. 1979;29:1253- S23-S27. mitte F, Agid Y. Does long-term...
Loading next page...
 
/lp/american-medical-association/levodopa-toxicity-svVYaA9U6M

References (2)

Publisher
American Medical Association
Copyright
Copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
2168-6149
eISSN
2168-6157
DOI
10.1001/archneur.57.3.410
Publisher site
See Article on Publisher Site

Abstract

25. Lesser RP, Fahn S, Snider SR, Cote LJ, Isgreen 27. Chase TN, Mouradian MM, Engber T. Motor re- early levodopa therapy in PD. Neurology. 1981; WP, Barrett RE. Analysis of the clinical problems sponse complications and the function of striatal 31:125-131. in parkinsonism and the complications of long- efferent systems. Neurology. 1993;43(suppl 6): 30. Bonet A-M, Loria Y, Santi-Hilaire M-H, Lher- term levodopa therapy. Neurology. 1979;29:1253- S23-S27. mitte F, Agid Y. Does long-term aggravation of 1260. 28. Peppe A, Dambrosia JM, Chase T. Risk factors for Parkinson’s disease result from nondopaminer- 26. De Jong GT, Meerwaldt JD, Schmitz PIM. Fac- motor response complications in L-dopa– gic lesions? Neurology. 1987;37:1539-1542. tors that influence the occurrence of response treated parkinsonian patients. Adv Neurol. 1993; 31. Shulman LM. Levodopa toxicity in Parkinson dis- variations in Parkinson’s disease. Neurology. 1990; 60:698-702. ease: reality or myth? reality—practice patterns 40:1344-1346. 29. Markham CH, Diamond SG. Evidence to support should change. Arch Neurol. 2000;57:406-407. EW DRUGS in medicine dyskinesia. She argues that fluctua- cause patients will not only contrib- have had the dramatic tions and dyskinesia were not de- ute to the answer but also receive impact of the introduc- scribed prior to the introduction

Journal

JAMA NeurologyAmerican Medical Association

Published: Mar 1, 2000

There are no references for this article.